Business
PepGen reports mixed results from DM1 trial, 10mg cohort ongoing
March 30, 2026
Investing.com
Scroll
Investing.com
Coverage and analysis from Israel. All insights are generated by our AI narrative analysis engine.
Israel
Bias: center
Coverage and analysis from Israel. All insights are generated by our AI narrative analysis engine.